Report of Foreign Issuer (6-k)
June 17 2016 - 4:23PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2016
Commission File Number 001-36866
SUMMIT
THERAPEUTICS PLC
(Translation of registrants name into English)
85b Park Drive
Milton
Park, Abingdon
Oxfordshire OX14 4RY
United Kingdom
(Address
of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or
Form 40-F: FORM 20-F
x
FORM 40-F
¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation
S-T Rule 101(b)(1):
¨
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7):
¨
Indicate by check mark whether the
registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: YES
¨
NO
x
If Yes is
marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
On June 17, 2016, Summit Therapeutics plc (the Company) issued a press release announcing that
its Annual Report and Accounts (the UK Annual Report) for the year ended January 31, 2016, together with the Notice of Annual General Meeting (the Notice), have been posted to shareholders. The UK Annual Report and
Notice are available to download or to print from the Investor Relations section of the Companys website at www.summitplc.com. The press release is attached as Exhibit 99.1.
On June 17, 2016, the Company issued a press release announcing that it has enrolled the first patient in PhaseOut DMD, a Phase 2 proof of concept
clinical trial of ezutromid in patients with Duchenne muscular dystrophy. The press release is attached as Exhibit 99.2.
The information contained in
Exhibit 99.1, the UK Annual Report, the Notice and Exhibit 99.2 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
SUMMIT THERAPEUTICS PLC
|
|
|
By:
|
|
/s/ Erik Ostrowski
|
|
|
Erik Ostrowski
Chief Financial
Officer
|
Date: June 17, 2016
EXHIBIT INDEX
|
|
|
Exhibit Number
|
|
Description
|
|
|
99.1
|
|
Press Release dated June 17, 2016 relating to the UK Annual Report and Annual General Meeting
|
|
|
99.2
|
|
Press Release dated June 17, 2016 relating to PhaseOut DMD
|
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024